163 related articles for article (PubMed ID: 10340923)
21. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.
Dorado P; Heras N; Machín E; Hernández F; Teran E; Llerena A
Eur J Clin Pharmacol; 2012 May; 68(5):637-44. PubMed ID: 22083166
[TBL] [Abstract][Full Text] [Related]
22. Induction of CYP2D6 in pregnancy.
Wadelius M; Darj E; Frenne G; Rane A
Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
[TBL] [Abstract][Full Text] [Related]
23. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
24. CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity.
Gutiérrez Rico EM; Kikuchi A; Saito T; Kumondai M; Hishinuma E; Kaneko A; Chan CW; Gitaka J; Nakayoshi T; Oda A; Saito S; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2020 Feb; 35(1):89-101. PubMed ID: 32037159
[TBL] [Abstract][Full Text] [Related]
25. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
Huang J; Chuang SK; Cheng CL; Lai ML
Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
[TBL] [Abstract][Full Text] [Related]
27. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
28. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
29. [Allele specific amplification for CYP2D6 gene related to intermediate metabolizer in Chinese subjects].
Chen B; Cai WM; Ling SS
Yao Xue Xue Bao; 2001 Feb; 36(2):88-91. PubMed ID: 12579870
[TBL] [Abstract][Full Text] [Related]
30. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population.
Mitsunaga Y; Kubota T; Ishiguro A; Yamada Y; Sasaki H; Chiba K; Iga T
Mutat Res; 2002 Aug; 505(1-2):83-5. PubMed ID: 12175908
[TBL] [Abstract][Full Text] [Related]
31. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
32. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
33. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Gaedigk A; Bradford LD; Alander SW; Leeder JS
Drug Metab Dispos; 2006 Apr; 34(4):563-9. PubMed ID: 16415111
[TBL] [Abstract][Full Text] [Related]
35. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
[TBL] [Abstract][Full Text] [Related]
36. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.
Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060
[TBL] [Abstract][Full Text] [Related]
37. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.
Köhler D; Härtter S; Fuchs K; Sieghart W; Hiemke C
Pharmacogenetics; 1997 Dec; 7(6):453-61. PubMed ID: 9429230
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
